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Background: Accurate diagnosis of urogenital schistosomiasis is vital for surveillance/control programs.
Amplification of schistosome DNA in urine by PCR is sensitive and specific but requires infrastructure, financial
resources and skilled personnel, often not available in endemic areas. Recombinase Polymerase Amplification (RPA)
is an isothermal DNA amplification/detection technology that is simple, rapid, portable and needs few resources.
Findings: Here a Schistosoma haematobium RPA assay was developed and adapted so that DNA amplicons could
be detected using oligochromatographic Lateral Flow (LF) strips. The assay successfully amplified S. haematobium
DNA at 30–45 °C in 10 mins and was sensitive to a lower limit of 100 fg of DNA. The assay was also successful with
the addition of crude urine, up to 5 % of the total reaction volume. Cross amplification occurred with other
schistosome species but not with other common urine microorganisms.
Conclusion: The LF-RPA assay developed here can amplify and detect low levels of S. haematobium DNA.
Reactions are rapid, require low temperatures and positive reactions are interpreted using lateral flow strips,
reducing the need for infrastructure and resources. This together with an ability to withstand inhibitors within urine
makes RPA a promising technology for further development as a molecular diagnostic tool for urogenital
schistosomiasis.
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Introduction
Schistosoma haematobium is one of three major human
schistosome species and causes >110 million cases of uro-
genital schistosomiasis throughout Africa, parts of the
Middle East, Madagascar, the Indian Ocean Islands and
more recently Corsica. Infection can result in, hematuria,
bladder wall pathology, hydronephrosis leading to severe
kidney disease [1, 2] and bladder cancer [3]; in addition,
an estimated 16 million women suffer from female genital
schistosomiasis (FGS), which can cause complications in
relation to fertility and HIV transmission [4].
Sensitive and specific diagnostic tests are critical for the
development and success of schistosomiasis control and
elimination programs. They not only enable the accurate* Correspondence: b.webster@nhm.ac.uk
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provide accurate surveillance data necessary to assess the
effectiveness of control interventions and to detect resur-
gence [5]. Moreover, as a control program achieves success,
low infection intensity is common increasing the need for
improved diagnostic sensitivity and specificity to prevent
false negative diagnosis [6–10].
Various modalities for the diagnosis and surveillance
of urogenital schistosomiasis are available but none
exhibit optimal performance characteristics for sensitive
and specific Point-Of-Care (POC) diagnosis [7–12]. Mo-
lecular diagnostics that target and amplify schistosome
DNA from within urine and stool samples potentially offer
high sensitivity and specificity [7, 8, 13, 14]. However, these
methods are costly, do require significant laboratory infra-
structure and technical ability, which can restrict their use
in endemic field settings [15].
Recombinase polymerase amplification (RPA) is an iso-
thermal DNA amplification technology offering severalis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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cially in terms of its application in more basic laboratory
settings in the field. The recombinase polymerase reaction
is specific, robust and can take place at an ambient
temperature [16, 17]. DNA amplification can be detected
by oligochromatographic lateral flow (LF) strips or real
time fluorescence, which offers detection flexibility and
utility in endemic settings [18]. Here we describe a pilot
project investigating the viability of RPA to amplify the S.
haematobium Dra1 DNA region [19]. The assays specifi-
city and sensitivity were investigated together with its abil-
ity to withstand PCR inhibitors found within crude urine.RPA Assay development
Suitable (30–35 bp, GC content 30–70 %) RPA primers
were designed (using Primer3 (http://primer3.ut.ee/)), to
target 110–120 bp of the S. haematobium Dra1
(www.ncbi.nlm.nih.gov/genbank, GenBank: DQ157698.1)
DNA region.
Combinations of the different RPA forward and reverse
primers were tested for their ability to amplify the Dra1
repeat region using the TwistAmp Basic kit (TwistDx, UK),
with slight modifications to the manufacturer’s protocol. 1X
rehydration buffer and dH2O was added to the dry enzyme
pellet and thoroughly mixed. 10 μM of each forward and
reverse primer was added together with 1 ng of template S.
haematobium gDNA (Senegal strain from the Schistosom-
iasis Collection at the Natural History Museum (SCAN)
[19]) and the reaction was initiated by addition of 280 mM
of magnesium acetate. Reactions were incubated at 37 °C
with constant shaking at 300 rpm in a Minitron shaker
(Infors, Switzerland) for 20 min. The reactions were puri-
fied with a QIAquick PCR Purification Kit (Qiagen,
USA) and then visualised on a 4 % agarose gel. The
primer pair, Dra-RPA-F1 + R1 (Table 1), demonstrated
the best target amplification (111 bp), producing
amplicon bands of increasing size representing multi-
ples of the original target sequence [20] (Fig. 1). The
sensitivity of the assay was evaluated with a detection







Features: Z = Biotin label; Y = 6-carboxyfluorescein (FAM) label; H = abasic tetrahydr
the instructions from TwistDx (http://www.twistdx.co.uk). The Dra1 LF probe was de
to the abasic tetrahydrofuran (THF) residue (H). The RPA and LF RPA primers are th
RPA assayDra1 LF-RPA assay development
The Dra1_RPA_F1 + R1 primers were adapted for the LF-
RPA assay by labelling of the reverse primer with a 5′ biotin
residue and an internal RPA LF probe (Dra1 LF probe) was
designed according to the TwistDX guidelines (Table 1).
5 μM of each LF primer (Dra1-LF-F1 + R1), 5 μM of the
Dra1 LF probe (10 μM), 0.25 M betaine (Sigma Aldrich,
UK) was mixed with 1 x rehydration buffer, dH2O and
was added to the reaction pellet of the TwistAmp nfo kit
(TwistDX, UK). 1 ng of the template S. haematobium
DNA was added and the reaction was initiated by addition
of 280 mM of magnesium acetate. Reactions were incu-
bated at 37 °C in a Minitron shaker at 300 rpm for
20 min. After incubation, 1 μl of the amplification was di-
luted in the running buffer (Milenia Biotec, Germany) and
10 μl placed on the sample pad of a Genline Hybridetect
−1 LF strip (Milenia Biotec, Germany). The strips were
placed vertically into separate tubes containing 100 μl of
running buffer and incubated at room temperature with
the final result read at 5 min.
Detection of the Dra1 LF-RPA amplicons was observed
as a positive test line on the LF strips (Fig. 1b). Faint test
bands in the negative controls were sometimes observed if
the LF strips were left for too long before being read, creat-
ing false positives. Increasing the amplicon dilution in the
running buffer to a ratio of 1 in 100 from the recom-
mended 1 in 50 abrogated this problem. The sensitivity of
Dra1 LF-RPA assay was evaluated with a limit of detection
observed at 100 fg of DNA (Fig. 1b). The effect of varying
reaction temperatures and times were also assessed. The
assay was found to operate over a temperature range of
30–45 °C, with reduced amplification at lower temperatures
and no amplification at 50 °C (Fig. 2a). Amplification was
detectable after as little as 5 min of incubation and optimal
amplification was reached at 10 min (Fig. 2b).
Effect of crude urine
Increasing volumes (0.31 μl, 0.63 μl, 1.25 μl and 2.50 μl)
(Table 2) of donor urine were spiked with 100 fg and also
10 pg of S. haematobium gDNA before being added to the







ofuran (THF) residue; 3 = C3 spacer. All primers were designed according to
signed with a recommended length of 46–52 bp with at least 30 bp placed 5′
e same but with a 5′ modification on the reverse primer (Dra1-R1-LF) for the LF
Control line
Test line
A                                                                                    B
Fig. 1 a Agarose gel image of the Dra1 RPA amplicons. Low limit of detection can be seen at 100 fg of S. haematobium gDNA. b LF strips showing
the detection of the Dra LF-RPA amplicons. Lower limit of detection can be seen at 100 fg of S. haematobium gDNA. NC = Negative control.
The LF-RPA oligonucleotides consisted of a forward primer, a specialised 6-FAM labelled oligonucleotide probe and a reverse biotin labelled primer.
Upon successful binding to the complementary gDNA target, amplification ensues resulting in the formation of a double-labelled amplicon. When run on
an oligochromatographic LF strip, the amplicon binds to anti-FAM antibodies and antibody labelled gold colloid nanoparticles in the running buffer bind
to the biotin antigen resulting in a semi quantitative colour change. The LF strip also has a control line to test for reaction failure
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of crude urine within the reactions ranged from 1 to 10 %.
With 100 fg of S. haematobium gDNA the addition of
1.25 % urine had no impact upon amplification efficacy. A
marked reduction in amplification efficacy was qualitatively
noted at 2.5 % and 5 % of total reaction volume and no
amplification was visible at 10 %. In contrast gDNA levels
of 10 pg increased the assays efficacy with significant ampli-
fication being detected even at 10 % of total reaction vol-
ume of urine.
Specificity
Cross amplification was observed with 1 pg of S. curassoni
and S. bovis DNA and at a higher limit of 100 pg for S.
mansoni (samples supplied by SCAN [19]). No cross amp-
lification was seen with Escherichia coli, KlebsiellaA                                                      
Control line
Test line
Fig. 2 LF strips showing Dra1 LF-RPA amplicon detection at different reactpneumoniae, Proteus mirabilis (cultures supplied by
the Microbiology Department, University Hospitals of
Leicester) and human gDNA (www.promega.com).
Discussion
The detection of species specific gDNA from urine is the
sensitive and specific current marker of true S. haemato-
bium infection [21]. RPA is an alternative gDNA based
diagnostic tool that overcomes several of the obstacles en-
countered by traditional gDNA based diagnostics [16–18],
particularly suiting it to Point-Of-Care (POC) use [22]. All
reagents are readily available lyophilized with the main
RPA reagents provided in a single dried pellet, which sim-
plifies assay preparation and allows easy transportation
and long-term storage at room temperature. DNA ampli-
fication is quick, requiring low ambient temperatures and                            B
Control line
Test line
ion temperatures (a) and times (b)
Table 2 Results showing the impact of crude urine on the efficacy of the Dra1 RPA-LF assay and subsequent LF detection. All reactions
were performed at 37 °C for 20 mins
Measure of crude urine in each Dra1 RPA-LF reaction Dra1 RPA-LF efficacy
Volume of crude urine (μl) % of crude urine Amount of S. haematobium gDNA
10 pg 100 fg
0.31 1.25 % +++ +++
0.63 2.5 % +++ ++
1.25 5 % +++ +
2.50 10 % +++ -
The number of + refers to the qualitative signal on the LF test line. +++ = very strong and - = no trace
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and portable to use, with results easily interpreted by
personnel with little training [16–18].
Here, RPA was successfully developed to amplify the
Dra1 DNA region of S. haematobium and amplification
success was easily detected by a semi quantitative colouri-
metric change on LF strips. Amplification was detectable
after only 5 min of incubation and at 30 °C, thus incubation
using human body heat, ambient environmental tempera-
tures in endemic areas or battery powered devices would
suffice, removing the need for external power supplies and
infrastructure [22].
The current LF-RPA sensitivity was lower than existing
Dra1 amplification assays [21]. However, theoretically RPA
can detect single template DNA copies thus there is scope
for further LF-RPA optimisation and development to in-
crease the sensitivity of the assay to achieve that achieved
with RT-PCR and LAMP [21]. RPA offers degrees of toler-
ance to inhibitors, such as those found in urine [17] sug-
gesting direct testing of untreated urine from infected
people will be feasible. The RPA’s reaction mechanisms
and chemistry means that total purification of total
DNA from samples is not required [17], reducing the
need for expensive, technical and time-consuming
sample DNA preparation / purification, enhancing its
feasibility in a POC situation [23]. The current cost per
test is high at approximately $5 (reaction + detection)
however, RPA is a newly developed technique and prices
are likely to decrease in the future while availability and
throughput will increase. For example centrifugal micro-
fluidic cartridges that can split a single reaction to enable
testing of eight individual samples have been developed
[22] reducing the cost to $0.6.
The Dra1 LF-RPA specificity to schistosome DNA was
high with no cross-reaction with Enterobacteria or human
gDNA. As found previously with RT-PCR [24], RPA Dra1
cross-amplification with S. mansoni was 1000 fold less
sensitive than for S. haematobium but as predicted cross-
amplification was successful with S. curassoni and S. bovis,
both members of the S. haematobium group, known to
possess the Dra1 repeat sequence [25]. Thus there is po-
tential to utilise this assay and / or develop alternativespecies-specific assays for the identification of other S.
haematobium-group species infections in livestock and
humans.
In conclusion, the Dra1 LF-RPA assay developed here
provides a robust S. haematobium DNA amplification
system offering advantages over currently available DNA
diagnostic systems; requiring minimal infra structure,
equipment, technical support, sample preparation and is
tolerant to inhibitors in crude urine. With further devel-
opment this assay has potential for POC diagnosis of uro-
genital schistosomiasis in endemic field settings.
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